The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. (Q50510141)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Didier Bouscary

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Jerome Tamburini

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sophie Park

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Nicolas Chapuis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Norbert Ifrah

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Alexa S Green

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sophie Grabar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Micheline Tulliez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Chadi Al-Nawakil

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Nathalie Jacque

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Nabih Azar

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

François Dreyfus

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Catherine Lacombe

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Patrick Mayeux

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

14 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

547-550

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21995271%20AND%20SRC:MED&resulttype=core&format=json

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

eIF-4E expression and its role in malignancies and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08891.X